Results of vardenafil mediated power Doppler ultrasound, contrast enhanced ultrasound and systematic random biopsies to detect prostate cancer
- PMID: 21496853
- DOI: 10.1016/j.juro.2011.02.014
Results of vardenafil mediated power Doppler ultrasound, contrast enhanced ultrasound and systematic random biopsies to detect prostate cancer
Abstract
Purpose: We evaluated the ability of the phosphodiesterase-5 inhibitor vardenafil to increase prostate microcirculation during power Doppler ultrasound. We also evaluated the results of contrast and vardenafil enhanced targeted biopsies compared to those of standard 12-core random biopsies to detect cancer.
Materials and methods: Between May 2008 and January 2010, 150 consecutive patients with prostate specific antigen more than 4 ng/ml at first diagnosis with negative digital rectal examination and transrectal ultrasound, and no clinical history of prostatitis underwent contrast enhanced power Doppler ultrasound (bolus injection of 2.4 ml SonoVue® contrast agent), followed by vardenafil enhanced power Doppler ultrasound (1 hour after oral administration of vardenafil 20 mg). All patients underwent standard 12-core transrectal ultrasound guided random prostate biopsy plus 1 further sampling from each suspected hypervascular lesion detected by contrast and vardenafil enhanced power Doppler ultrasound.
Results: Prostate cancer was detected in 44 patients (29.3%). Contrast and vardenafil enhanced power Doppler ultrasound detected suspicious, contrast enhanced and vardenafil enhanced areas in 112 (74.6%) and 110 patients (73.3%), and was diagnostic for cancer in 32 (28.5%) and 42 (38%), respectively. Analysis of standard technique, and contrast and vardenafil enhanced power Doppler ultrasound findings by biopsy core showed significantly higher detection using vardenafil vs contrast enhanced power Doppler ultrasound and standard technique (41.2% vs 22.7% and 8.1%, p <0.005 and <0.001, respectively). The detection rate of standard plus contrast or vardenafil enhanced power Doppler ultrasound was 10% and 11.7% (p not significant).
Conclusions: Vardenafil enhanced power Doppler ultrasound enables excellent visualization of the microvasculature associated with cancer and can improve the detection rate compared to contrast enhanced power Doppler ultrasound and the random technique.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Colour Doppler and microbubble contrast agent ultrasonography do not improve cancer detection rate in transrectal systematic prostate biopsy sampling.BJU Int. 2011 Dec;108(11):1723-7. doi: 10.1111/j.1464-410X.2011.10199.x. Epub 2011 Jul 14. BJU Int. 2011. PMID: 21756276 Clinical Trial.
-
Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score.J Urol. 2007 Aug;178(2):464-8; discussion 468. doi: 10.1016/j.juro.2007.03.107. Epub 2007 Jun 11. J Urol. 2007. PMID: 17561137
-
Contrast-enhanced ultrasonography using cadence-contrast pulse sequencing technology for targeted biopsy of the prostate.BJU Int. 2009 Feb;103(4):458-63. doi: 10.1111/j.1464-410X.2008.08038.x. Epub 2008 Nov 18. BJU Int. 2009. PMID: 19021610
-
Enhanced transrectal ultrasound modalities in the diagnosis of prostate cancer.Urology. 2010 Nov;76(5):1025-33. doi: 10.1016/j.urology.2010.05.022. Epub 2010 Aug 16. Urology. 2010. PMID: 20719368 Review.
-
Value of contrast-enhanced ultrasound and elastography in imaging of prostate cancer.Curr Opin Urol. 2007 Jan;17(1):39-47. doi: 10.1097/MOU.0b013e328011b85c. Curr Opin Urol. 2007. PMID: 17143110 Review.
Cited by
-
The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigen (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and meta-analysis.Cent European J Urol. 2021;74(3):388-421. doi: 10.5173/ceju.2021.132.R1. Epub 2021 Aug 11. Cent European J Urol. 2021. PMID: 34729231 Free PMC article.
-
Phosphodiesterase Type 5 Inhibitors in Male Reproduction: Molecular Mechanisms and Clinical Implications for Fertility Management.Cells. 2025 Jan 15;14(2):120. doi: 10.3390/cells14020120. Cells. 2025. PMID: 39851548 Free PMC article. Review.
-
Image guidance in the focal treatment of prostate cancer.Curr Opin Urol. 2012 Jul;22(4):328-35. doi: 10.1097/MOU.0b013e32835482cc. Curr Opin Urol. 2012. PMID: 22647649 Free PMC article. Review.
-
Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action.Ther Adv Urol. 2015 Oct;7(5):249-64. doi: 10.1177/1756287215589238. Ther Adv Urol. 2015. PMID: 26425140 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical